 Clinical studies have shown that this emerging biology of inflammation in atherosclerosis applies directly to human patients.Elevation in markers of inflammation predicts outcomes of patients with acute coronary syndromes, independently of myocardial damage.In addition, low-grade chronic inflammation, as indicated by levels of the inflammatory marker C-reactive protein, prospectively defines risk of atherosclerotic complications, thus adding to prognostic information provided by traditional risk factors.